🇺🇸 FDA
Patent

US 9744169

Compounds for treatment of fibrosis diseases

granted A61KA61K31/444A61K31/4725

Quick answer

US patent 9744169 (Compounds for treatment of fibrosis diseases) held by Curegenix, Inc. expires Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Curegenix, Inc.
Grant date
Tue Aug 29 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K31/444, A61K31/4725, A61K31/497, A61K31/4985